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Abstract
Two subtypes of phospholipases A2 (PLA2s) with the ability to induce myonecrosis, ‘Asp49’ and ‘Lys49’ myotoxins, often
coexist in viperid snake venoms. Since the latter lack catalytic activity, two different mechanisms are involved in their
myotoxicity. A synergism between Asp49 and Lys49 myotoxins from Bothrops asper was previously observed in vitro,
enhancing Ca2+ entry and cell death when acting together upon C2C12 myotubes. These observations are extended for the
first time in vivo, by demonstrating a clear enhancement of myonecrosis by the combined action of these two toxins in
mice. In addition, novel aspects of their synergism were revealed using myotubes. Proportions of Asp49 myotoxin as low as
0.1% of the Lys49 myotoxin are sufficient to enhance cytotoxicity of the latter, but not the opposite. Sublytic amounts of
Asp49 myotoxin also enhanced cytotoxicity of a synthetic peptide encompassing the toxic region of Lys49 myotoxin. Asp49
myotoxin rendered myotubes more susceptible to osmotic lysis, whereas Lys49 myotoxin did not. In contrast to myotoxic
Asp49 PLA2, an acidic non-toxic PLA2 from the same venom did not markedly synergize with Lys49 myotoxin, revealing a
functional difference between basic and acidic PLA2 enzymes. It is suggested that Asp49 myotoxins synergize with Lys49
myotoxins by virtue of their PLA2 activity. In addition to the membrane-destabilizing effect of this activity, Asp49 myotoxins
may generate anionic patches of hydrolytic reaction products, facilitating electrostatic interactions with Lys49 myotoxins.
These data provide new evidence for the evolutionary adaptive value of the two subtypes of PLA2 myotoxins acting
synergistically in viperid venoms.
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Introduction
Phospholipases A2 (PLA2s) are widespread enzymes in snake
venoms, where they play major toxic roles in the immobilization
and/or killing of prey [1,2]. Among their diverse activities,
myotoxicity is a clinically relevant effect which may lead to severe
tissue damage and associated sequelae in envenomings [3–5]. Two
divergent ancestral PLA2 genes representing the group I and
group II scaffolds, respectively, were recruited and expressed in the
venom gland secretions of Elapidae and Viperidae [6]. Through a
process of accelerated evolution [7], these genes accumulated
mutations that converted their corresponding non-toxic proteins
into potent toxins, most notably displaying neurotoxicity and/or
myotoxicity. The independent emergence of such toxic activities in
these two lineages of advanced snakes illustrates a case of
convergent evolution [8,9]. A growing body of knowledge has
been gathered on the characterization of PLA2 toxins, but the
structural bases for their toxicity and precise modes of action
remain only partially understood, thus leaving opened a number of
challenging questions [10].
In the venoms of viperid snakes, two subtypes of myotoxic
PLA2s can be found, commonly referred to as ‘Asp49’ and ‘Lys49’
variants. The latter, first described in the venom of Agkistrodon
piscivorus piscivorus [11] and then isolated from many viperid
venoms [9], present the substitution of Asp49 by Lys49, a critical
change in the catalytic center of the molecule which, together with
key amino acid substitutions located in the calcium-binding loop,
precludes catalysis [12–14]. Therefore, in sharp contrast with their
Asp49 PLA2 counterparts, the Lys49 myotoxins are enzymatically-
inactive PLA2 homologues, or ‘PLA2-like’ proteins [13,15–18].
Notwithstanding their difference in catalytic activity, both Lys49
and Asp49 PLA2 variants display myotoxicity in vivo [4,19–21].
The Asp49 PLA2s depend on their enzymatic activity to induce
skeletal muscle damage, since their catalytic inactivation by
covalently modifying His48 with p-bromophenacyl bromide results
in the loss of myotoxicity [22–24]. Furthermore, the toxic effects of
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Asp49 PLA2s on myogenic cells in culture can be mimicked by the
products of their hydrolytic activity, i.e. fatty acids and lysopho-
spholipids [25], and hydrolysis of muscle phospholipids of the
external monolayer of the sarcolemma by these enzymes has been
demonstrated in myotubes in culture as well as in injected mouse
muscles [26]. On the other hand, the catalytic-independent
mechanism by which Lys49 PLA2 homologues induce myonecro-
sis, has been shown to depend on a cluster of amino acids at their
C-terminal region which directly affect the integrity of the
sarcolemma [9,18,27–32].
The venom of Bothrops asper, the snake species causing the
majority of envenomings in Central America [33], contains
multiple Asp49 and Lys49 myotoxin isoforms [34] as well as a
non-myotoxic, acidic Asp49 PLA2 [35]. In a previous study, a
synergistic action between purified Asp49 and Lys49 myotoxins
was observed in vitro, whereby these two proteins induced a more
pronounced Ca2+ entry and cell death by acting together, rather
than individually [25]. The present work extends these observa-
tions by exploring for the first time whether the same phenomenon
occurs in vivo, and characterizes in further detail relevant features
of this synergistic action using an in vitro model.
Materials and Methods
Isolation of phospholipases A2 from Bothrops asper
venom
Snake venom was collected from specimens kept at the
Serpentarium of Instituto Clodomiro Picado, under authorization
of the University of Costa Rica. Pooled venom of Bothrops asper
from the Pacific versant of Costa Rica was fractionated as
previously described, to obtain myotoxin II (Lys49; UniProt
accession P24605; [36,37]), a mixture of myotoxins I/III (Asp49;
P20474; [24,38]), and an acidic BaspPLA2-II (non-myotoxic,
Asp49; P86389; [35]). Fractionation steps included ion-exchange
chromatography followed by semi-preparative reverse-phase
HPLC on a C8 support. Purity was assessed by nano-electrospray
mass spectrometry in a QTrap-3200 instrument (ABSciex)
operated in positive ion-enhanced multicharge mode, as described
[24]. The lack of contaminating Asp49 PLA2s in the Lys49
myotoxin II preparation was evaluated by assaying PLA2 activity
using the synthetic substrate 4-nitro-3-octanoyloxybenzoic acid
[39]. Conversely, the lack of contaminating Lys49 myotoxins in
the basic Asp49 PLA2 myotoxin preparation was ascertained by
automated N-terminal amino acid sequencing using a PPSQ-33A
Figure 1. Cytotoxic activity of Asp49 and Lys49 myotoxins from Bothrops asper, alone or in combination, upon C2C12 myoblasts (A)
or myotubes (B). The indicated amounts of toxins were added in a total volume of 150 mL. Cytolysis was determined by the release of lactate
dehydrogenase to the medium 3 h after exposure of the cells to the toxins, as described in Materials and Methods. Reference values of 0 and 100%
cytolysis were established using medium or 0.1% Triton X-100 in medium, respectively. Each bar represents mean 6 SD of triplicate cell cultures.
Statistically significant differences (p,0.05) between two groups are indicated by dotted arrow lines.
doi:10.1371/journal.pone.0109846.g001
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instrument (Shimadzu Biotech), to confirm the absence of a
Leucine signal in the fifth cycle [24].
Asp49 PLA2 myotoxin inactivation by p-bromophenacyl
bromide
Three mg of the Asp49 myotoxin were dissolved in 1 mL of 0.1
M Tris, 0.7 mM EDTA, pH 8.0 buffer. Then, 125 mL of p-
bromophenacyl bromide (p-BPB; 1.5 mg/mL in ethanol; Sigma
Chemical Co.) were added and incubated at room temperature
(20–25uC) for 24 h [22]. Excess p-BPB and salts were eliminated
by RP-HPLC on a semi-preparative C8 column, as described [24].
The protein was collected and finally dried by vacuum centrifu-
gation at 45uC. Enzymatic inactivation was determined on the 4-
nitro-3-octanoyloxybenzoic acid substrate in comparison to a
control sample of the toxin which was processed identically but
omitting the p-BPB reagent [24].
Synthetic peptide of B. asper myotoxin II
A synthetic peptide from the C-terminal region of B. asper
myotoxin II, corresponding to the sequence 115–129 (KKYR-
YYLKPLCKK; p115–129), was obtained from a commercial
provider (Peptide 2.0, Inc.). The peptide was synthesized with
native endings by Fmoc chemistry, and its molecular mass was in
agreement with the expected value. Its purity level was at least
95% by RP-HPLC analysis. This 13-mer peptide has been shown
to reproduce, albeit with a lower potency, the cytolytic effect of
myotoxin II in vitro [27,29].
Cytotoxic activity
Cytolysis was determined on the murine myogenic cell line
C2C12 (ATCC-CRL1772) using a lactate dehydrogenase release
assay, as previously described [40]. Cells were grown at
subconfluent densities in 25 cm2 bottles using Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal calf serum (DMEM,
10% FCS), and after detachment by trypsin, they were seeded in
96-well plates for cytotoxicity assays. These were performed either
at the myoblast stage in near-confluent cell monolayers, or after
their differentiation to fused myotubes in DMEM 1% FCS during
4–6 additional days. In brief, different amounts of toxins, alone or
in combination, dissolved in 150 mL of assay medium (DMEM,
1% FCS) were added to the cells immediately after removal of
their medium, and incubated for 3 h at 37uC. Then, an aliquot of
cell supernatant (60 mL) was collected from each well and the
lactacte dehydrogenase (LDH) activity was quantified by a UV
kinetic assay (LDH-BR Cromatest, Linear Chemicals). Controls
for 0 and 100% cytotoxicity consisted of assay medium, and 0.1%
Figure 2. Myotoxic activity of Asp49 and Lys49 myotoxins from Bothrops asper, alone or in combination, injected by intramuscular
route in CD-1 mice. Plasma creatine kinase activity was determined 3 h after injection of the indicated amounts of toxins. Control mice received
only vehicle (PBS). Each bar represents mean 6 SD of five animals. Statistically significant differences (p,0.05) between two groups are indicated by
dotted arrow lines. Synergistic action is shown at a total dose of 10 mg in (A) or 20 mg in (B), respectively.
doi:10.1371/journal.pone.0109846.g002
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Triton X-100 diluted in assay medium, respectively. All samples
were assayed in triplicate wells.
Myotoxic activity
Myotoxic activity was determined in CD-1 mice of 18 to 20 g of
body weight, using five animals per group. These in vivo assays
were kept to a minimum, and followed protocols authorized by the
Institutional Committee for the Use and Care of Animals
(CICUA; #132-13), University of Costa Rica. Mice were housed
in cages for groups of 4–6, and provided food and water ad
libitum. Different amounts of the toxins, alone or in combination,
dissolved in 50 mL of phosphate-buffered saline (PBS; 0.12 M
NaCl, 0.04 M sodium phosphate buffer, pH 7.2), were injected
into the gastrocnemius muscle [36]. A control group of mice
received an identical injection of PBS. After 3 h, blood was
collected from the tip of the tail into a heparinized capillary and
centrifuged. The plasma creatine kinase (CK) activity, expressed in
U/L, was determined using a UV kinetic assay (CK-Nac, Biocon
Diagnostik). Mice were sacrificed by CO2 inhalation, at the end of
the experiment.
Statistical analysis
ANOVA was used for the comparison of mean values from
more than two groups, followed by Tukey-Kramer tests, with a
statistical significance of p,0.05. Calculations were performed
with the aid of the Instat (GraphPad) software.
Results
The cytolytic effect of Asp49 and Lys49 myotoxins, when added
alone or in combination to cultures of the C2C12 cell line at the
myoblast or myotube stages, is shown in Fig. 1. A higher effect of
these toxins was observed in myotubes than in myoblasts, and this
difference was more conspicuous in the case of the Asp49
myotoxin, which was extremely weak against myoblasts (Fig. 1A).
In both stages of cell differentiation, the combination of the
myotoxins induced a significantly higher cytotoxicity in compar-
ison to the effect of either toxin alone (Fig. 1). The observed effect
was clearly synergistic and not just additive. Following these
in vitro findings, experiments were performed in mice to
determine whether synergism also occurs in mature skeletal
muscle, under conditions that mimic envenomings. Results
revealed a clear enhancement of myotoxicity, as judged by the
higher release of creatine kinase from damaged muscle to the
Figure 3. Cytotoxic activity of p-bromophenacyl bromide-modified Asp49 myotoxin (Asp49pb) and Lys49 myotoxin, alone or in
combination at 10 mg (A) or 5 mg (B), upon C2C12 myotubes. The indicated amounts of toxins were added in a total volume of 150 mL.
Cytolysis was determined by the release of lactate dehydrogenase to the medium, 3 h after exposure of the cells to the toxins. Each bar represents
mean 6 SD of triplicate cell cultures. Statistically significant differences (p,0.05) between two groups are indicated by dotted arrow lines.
doi:10.1371/journal.pone.0109846.g003
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plasma, when the Asp49 and Lys49 toxins acted in combination
(Fig. 2). When injected individually, the myotoxic effect of the
Lys49 myotoxin was significantly higher than that of the Asp49
myotoxin at the dose of 20 mg (Fig. 2B), although at 10 mg
(Fig. 2A) this same trend did not reach statistical significance.
The role of enzymatic activity of the Asp49 myotoxin in the
synergistic effect was studied by using a p-BPB-treated enzyme.
This protein incorporated a single molecule of the alkylating
agent, as confirmed by mass spectrometry, and its catalytic activity
was inactivated by 97% in comparison to the untreated enzyme
[24]. As shown in Fig. 3, the cytolytic action of the p-BPB-treated
Asp49 myotoxin alone was negligible, as expected. However, the
combined action of this protein and the Lys49 myotoxin caused a
significant enhancement of the cytotoxic effect (Fig. 3). Since the
p-PBP-treated Asp49 protein had a residual enzymatic activity of
3%, further experiments were designed to determine whether the
synergistic effect observed in Fig. 3 could be due to this low
residual catalytic action or, alternatively, depended on a non-
catalytic mechanism of the Asp49 myotoxin. Therefore, low
amounts of native Asp49 myotoxin, within a range comparable to
the proportion of enzymatically-active protein remaining in the p-
PBP-treated toxin, were combined with a fixed amount of Lys49
myotoxin (Fig. 4). Results showed that Asp49 myotoxin amounts
as low as 0.12 mg (representing 1.2% in proportion to the Lys49
myotoxin), efficiently enhanced the cytotoxicity of the final
mixture. Importantly, these low amounts of Asp49 myotoxin were
essentially non-toxic when added alone to the myotube cultures
(Fig. 4). Further titration of the effect of Asp49 myotoxin in this
assay showed that the minimal amount of enzyme capable of
inducing synergism was 0.012 mg. The reverse combination, i.e.
addition of low quantities of Lys49 myotoxin to a fixed amount of
Asp49 myotoxin (Fig. 5) did not enhance toxicity, thus revealing
the directionality of the synergistic mechanism.
Since results indicated that the Asp49 myotoxin, even in low
amounts, enhanced the toxicity of the Lys49 myotoxin, an
experiment was performed to determine whether this synergy
was dependent on the time lapse when a low amount of the
enzyme was in contact with myotubes, before the addition of the
Lys49 myotoxin. The Asp49 enzyme was incubated with the cells
for the time periods indicated in Fig. 6 (0, 15, 30, or 60 min) and,
after five washings of the cell cultures, the Lys49 myotoxin was
added. A significant enhancement in cytotoxicity was recorded at
all time periods of cell exposure to the Asp49 myotoxin and,
remarkably, even when the Asp49 enzyme was added and the
cultures were immediately washed (Fig. 6).
Figure 4. Cytotoxic activity of a fixed amount of Lys49 myotoxin, alone or in combination with low amounts of Asp49 myotoxin,
upon C2C12 myotubes. The indicated amounts of toxins were added in a total volume of 150 mL. Cytolysis was determined by the release of
lactate dehydrogenase to the medium, 3 h after exposure of the cells to the toxins. Each bar represents mean 6 SD of triplicate cell cultures. All
values from cultures where the Lys49 myotoxin was added together with Asp49 myotoxin were significantly different (p,0.05) from the value of
cultures exposed only to Lys49 myotoxin (indicated by asterisks).
doi:10.1371/journal.pone.0109846.g004
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Since B. asper venom also contains non-myotoxic Asp49 PLA2s
whose role in venom’s toxicity is uncertain [35], the effect of a
non-myotoxic, acidic-type PLA2 on the cytotoxic activity of Lys49
myotoxin was investigated in the same assay system, as shown in
Fig. 7. As expected, the acidic Asp49 enzyme alone was not
cytotoxic. The combination of this enzyme with the Lys49
myotoxin caused a significant, although only modest increase at
5 mg, but at 10 mg was unable to significantly enhance cytotoxicity
of Lys49 myotoxin (Fig. 7).
The synergistic effect of a low amount of Asp49 myotoxin
toward the cytolytic action of the synthetic peptide p115–129 of the
Lys49 myotoxin was evaluated. As presented in Fig. 8, the
cytotoxicity induced by this short peptide was markedly enhanced
by acting in combination with the Asp49 enzyme.
Finally, the cytotoxic action of Asp49 and Lys49 myotoxins was
tested under conditions of osmotic imbalance of the cells. Culture
medium was rendered hypotonic by the addition of varying
proportions of purified water (8:2, 9:1, or 10:1 water:medium), and
cytolysis was determined in the absence or presence of the toxins.
As shown in Fig. 9A, myotubes exposed to a low amount of Asp49
myotoxin became significantly more susceptible to the deleterious
action of the hypotonic media, at 8:2 and 9:1 water:medium
proportions. At the 10:0 proportion (100% water), the high
cytolysis in the control cells did not allow the assessment of the
effect of myotoxin. In contrast, when the same experiment was
performed with Lys49 myotoxin, it revealed that this protein does
not alter the susceptibility of myotubes exposed to hypotonic
conditions, since similar values of cytolysis were observed in the
absence or in the presence of the toxin (Fig. 9B).
Discussion
The venoms of many viperid snake species contain variable
combinations of PLA2s, often including acidic and basic variants,
and among the latter, Asp49 and Lys49 myotoxin subtypes
[1,2,41]. Phylogenetic analyses indicate that the myotoxic Lys49
PLA2 homologues diverged from ancestral, group II Asp49 PLA2s
before the separation of Viperinae and Crotalinae [42–46].
Intriguingly, however, a comprehensive examination of the
bioactivities displayed by myotoxic Asp49 and Lys49 variants
does not provide evident clues on the possible evolutionary
advantages conferred by the emergence of the latter, since both
types of myotoxins share similar toxicological profiles and often
coexist in viperid venoms [41]. Nevertheless, the abundance and
common occurrence of these coexisting myotoxins in many viperid
species strongly suggest that they provided an important adaptive
value in this family of snakes. Several speculative hypotheses have
Figure 5. Cytotoxic activity of a fixed amount of Asp49 myotoxin, alone or in combination with low amounts of Lys49 myotoxin,
upon C2C12 myotubes. The indicated amounts of toxins were added in a total volume of 150 mL. Cytolysis was determined by the release of
lactate dehydrogenase to the medium, 3 h after exposure of the cells to the toxins. Each bar represents mean6 SD of triplicate cell cultures. None of
the values from cultures where the Asp49 myotoxin was added together with Lys49 myotoxin were significantly different from the value of cultures
exposed only to Asp49 myotoxin.
doi:10.1371/journal.pone.0109846.g005
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been proposed to envisage their possible biological significance
and adaptive value, one of them being synergism [41]. A
synergistic action upon myogenic cells in culture was first
described by Cintra-Francischinelli et al. [25] using the C2C12
cell line as a target for Asp49 and Lys49 myotoxins isolated from
the venom of B. asper. The present study extends such
observations by demonstrating the in vivo synergism between
these two toxin subtypes in the induction of myonecrosis, and
provides further insights into the mechanisms of this synergistic
effect.
In agreement with previous studies [47], a higher susceptibility
of myotubes over myoblasts to the cytotoxic action of the
myotoxins was observed. Also, myoblasts were more resistant to
the Asp49 than to the Lys49 myotoxin, as previously noted by
Cintra-Francischinelli et al. [25]. In agreement with their study, a
cytotoxic synergism between the two toxins was confirmed at both
stages of cell differentiation, i.e. myoblasts and myotubes. In order
to determine whether these in vitro observations would also apply
to the biologically-relevant target of myotoxins, i.e. skeletal muscle,
similar experiments were conducted in mice. Results demonstrate,
for the first time in vivo, a clear enhancement of myotoxicity by
the combined action of Asp49 and Lys49 myotoxins in comparison
to the effect of either protein alone. Therefore, these in vivo results
add new evidence for the adaptive value of the emergence of two
subtypes of PLA2 myotoxins in viperid venoms, conferring a
selective advantage in the light of the high energetic costs of venom
protein synthesis [48,49].
The in vivo synergism hereby shown helps to clarify previous
observations in the study of viperid PLA2 myotoxins, in which
crude venoms have generally been found to induce stronger
myonecrosis than their isolated myotoxins [50]. Although the
contribution to muscle damage of other toxin types in crude
venoms (for example hemorrhagic metalloproteinases that pro-
mote myonecrosis as a consequence of ischemia [51]) cannot be
excluded, the combined action of Asp49 and Lys49 myotoxins in
crude venoms may explain the higher magnitude of myonecrosis
Figure 6. Cytotoxic activity of a fixed amount of Lys49
myotoxin, alone or in combination with a low amount of
Asp49 myotoxin. In this experiment, Asp49 myotoxin was first
incubated for variable periods of time with C2C12 myotubes, and then
washed five times, before the addition of Lys49 myotoxin. The indicated
amounts of toxins were added in a total volume of 150 mL. Cytolysis
was determined by the release of lactate dehydrogenase to the
medium 3 h after exposure of the cells to the toxins. Each bar
represents mean6 SD of triplicate cell cultures. All values from cultures
where the Lys49 myotoxin was added together with Asp49 myotoxin
were significantly different (p,0.05) from the value of cultures exposed
only to Lys49 myotoxin (indicated by asterisks).
doi:10.1371/journal.pone.0109846.g006
Figure 7. Cytotoxic activity of Bothrops asper acidic Asp49
phospholipase A2 (PLA2
ac) and Lys49 myotoxin, alone or in
combination, upon C2C12 myotubes. The indicated amounts of
toxins were added in a total volume of 150 mL. Cytolysis was
determined by the release of lactate dehydrogenase to the medium,
3 h after exposure of the cells to the toxins. Each bar represents mean
6 SD of triplicate cell cultures. Statistically significant differences (p,
0.05) between two groups are indicated by dotted arrow lines.
doi:10.1371/journal.pone.0109846.g007
Figure 8. Cytotoxic activity of Asp49 myotoxin and the
synthetic C-terminal peptide p115–129 of Lys49 myotoxin II
from Bothrops asper, alone or in combination, upon C2C12
myotubes. The indicated amounts of toxin or synthetic peptide were
added in a total volume of 150 mL. Cytolysis was determined by the
release of lactate dehydrogenase to the medium, 3 h after exposure of
the cells to the toxins. Each bar represents mean 6 SD of triplicate cell
cultures. Statistically significant differences (p,0.05) between two
groups are indicated by dotted arrow lines.
doi:10.1371/journal.pone.0109846.g008
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observed in comparison to experiments analyzing isolated
myotoxins. Also noteworthy, the extent of muscle damage induced
by the Lys49 myotoxin was higher than that caused by the Asp49
myotoxin. This result is in agreement with the proposal that Lys49
PLA2 homologues in viperids provided an adaptive value due to
their increased myotoxic potency, as discussed by Kihara et al.
[52]. From the biological standpoint, an enhanced capacity to
induce acute muscle damage might contribute to a more efficient
digestion of the abundant muscle mass characteristic of mamma-
lian prey [41].
In order to determine whether the synergistic mechanism
depends on the PLA2 activity of Asp49 myotoxins, this enzyme
was inactivated by p-BPB [22,24]. As expected, the modified
enzyme essentially lost its cytotoxic effect upon myotubes, but
surprisingly, still enhanced the cytotoxic action of the Lys49
myotoxin. This prompted us to evaluate the residual catalytic
activity of the p-BPB-treated protein, which revealed a low, but
detectable hydrolysis of the 4-nitro-3-octanoyloxybenzoic acid
substrate, estimated at the level of 3% of the unmodified toxin. On
this basis, it was hypothesized that such low residual catalytic
activity could either be sufficient for the occurrence of synergism,
or, alternatively, the synergistic action recorded for the p-BPB-
modified enzyme would be caused by a catalytically-independent
mechanism. To address this point, the synergism was subsequently
tested with low amounts of the Asp49 PLA2, mimicking the
proportion of the corresponding residual enzymatic activity of the
p-BPB-treated myotoxin. Results confirmed that these minute
amounts of the Asp49 PLA2, in sublytic concentrations per se, are
able to enhance the cytolytic effect of the Lys49 myotoxin.
Therefore, the mechanism of synergism can be attributed to the
enzymatic action of the Asp49 PLA2, rather than a catalytically-
independent activity. A similar conclusion was reached by Cintra-
Francischinelli et al. [25] by observing that, in the absence of
external Ca2+, the Asp49 myotoxin was unable to synergize with
the Lys49 myotoxin due to the requirement of this ion for
enzymatic activity. Moreover, the present observations underscore
that even a very low enzymatic activity of Asp49 myotoxins is
enough for the observed synergism. The directionality of this
‘micro-synergism’ was determined to be an enhancement of the
Lys49 myotoxin toxicity by the Asp49 enzyme, and not the
converse, since low quantities of the Lys49 myotoxin did not
increase the toxic action of the Asp49 enzyme.
Using this experimental model of ‘micro-synergism’, additional
aspects of the mechanisms involved were explored. Since the
enhancing action of the Asp49 enzyme was found to depend on its
catalytic activity, an experiment was designed to evaluate the effect
of time by which cells were exposed to the enzyme, then washed,
and finally exposed to the Lys49 myotoxin. The addition of a low
amount of the Asp49 PLA2, independently of the time of contact
with the cells, and even when washing was performed immediately
after toxin addition, led to a similar cytotoxic outcome. One
possibility to explain these findings would be that the enzyme
binds rapidly and tightly to the cell membrane interface, and is not
removed by gentle washing, thus continuing its enzymatic
phospholipid hydrolysis. The assessment of this hypothesis awaits
experiments on the binding of myotoxins to myotubes.
Considering that the venom of B. asper contains, in addition to
basic PLA2s, an acidic Asp49 PLA2 enzyme which is devoid of
myotoxicity (BaspPLA2-II [35]), it was of interest to evaluate
whether this enzyme would be able to synergize with the basic
Lys49 myotoxin. In agreement with its previous characterization,
this acidic PLA2 did not induce cytotoxicity per se. Interestingly,
this acidic PLA2 did not induce the marked synergistic effect
observed with the basic Asp49 PLA2. Only a minor increase in
cytotoxicity was observed when using 5 mg of the enzyme, and
twice this amount did not result in a statistically significant
difference of toxicity in comparison to the Lys49 myotoxin alone.
This result is noteworthy because the acidic enzyme displays a
higher catalytic activity than the Asp49 myotoxin [35]. This
suggests that the acidic enzyme might be unable to hydrolyze the
membrane phospholipids of myotubes, which in turn would
explain both its lack of toxicity and its inability to synergize
effectively with Lys49 myotoxin in this model. This hypothesis
awaits the study of phospholipid hydrolysis in the membranes of
myotubes and muscle cells by using highly sensitive methodologies
such as mass spectrometry [26]. Hence, the role of this non-
cytotoxic acidic PLA2 in the overall toxicity of the venom of B.
asper, if any, remains uncertain.
A key question arising from the present and previous studies on
the synergism between Asp49 PLA2 and Lys49 myotoxins
concerns how does the enzymatic activity of the former enhance
the toxicity of the latter. To the best of our knowledge, the first
evidence of a synergism between these two myotoxin subtypes was
reported by Shen and Cho [53], who demonstrated that an Asp49
PLA2 from A. p. piscivorus venom enhanced the liposome-
permeabilizing effect of a Lys49 PLA2 homologue isolated from
the same source. These authors proposed that the Asp49 enzyme
would generate anionic patches of hydrolytic reaction products on
the surface of the liposomes, which in turn would facilitate the
Figure 9. Cytotoxic activity of Asp49 and Lys49 myotoxins
upon C2C12 myotubes under conditions of osmotic imbalance.
Myotubes were grown and differentiated as described in Methods, and
then the toxins (0.5 mg) were added to cultures using medium that
contained the indicated proportion of water (gray bars). (A) Asp49
myotoxin, (B) Lys49 myotoxin. Control cultures exposed to the same
medium conditions, in the absence of toxin, were tested in parallel
(empty bars). Cytolysis was determined by the release of lactate
dehydrogenase to the medium after 3 h. Each bar represents mean 6
SD of triplicate cell cultures. Statistically significant differences (p,0.05)
between two groups are indicated by dotted arrow lines.
doi:10.1371/journal.pone.0109846.g009
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electrostatic interaction with the Lys49 protein, and the conse-
quent permeabilization of the vesicle by the non-enzymatic,
bilayer penetrating mechanism of the latter [53]. A second, non-
mutually exclusive explanation for the synergistic mechanism was
proposed [25], whereby the products of phospholipid hydrolysis
generated by the Asp49 myotoxin would enhance the toxicity of
the Lys49 myotoxin by rendering the cell membrane more
unstable, based on the observation that a mixture of lysopho-
spholipids and fatty acids can mimic per se the membrane-
damaging effects of Asp49 myotoxin.
In the present study, two further observations shed light into the
possible mechanisms of the synergy here characterized. First, the
bioactive C-terminal synthetic peptide of the Lys49 myotoxin,
p115–129, reproduced the synergy phenomenon observed with the
parent protein, i.e. the concomitant addition of a low amount of
Asp49 PLA2 and peptide resulted in a significant enhancement of
myotube cell lysis. Since this peptide is highly cationic [27], this
finding (as well as results with the parent Lys49 myotoxin) would
be compatible with the hypothesis that proposed the generation of
new anionic sites by the Asp49 enzyme [53], thus facilitating the
electrostatic interaction of the peptide or the toxin with the
membrane [54,55], and ultimately its permeabilization [8,25,56].
However, the higher cytotoxic effect of the peptide when acting in
synergy with the Asp49 myotoxin might as well be explained by
the weakening of membrane stability caused by the catalytic action
of the enzyme and by the generation of fatty acids and
lysophospholipids. Thus, results of this experiment would be
compatible with both mechanisms. The hypothesis of a general
membrane-destabilizing effect caused by phospholipid hydrolysis
and generation of products that alter its biophysical properties [25]
is hereby experimentally supported. It was hypothesized that, if the
myotube cell membrane becomes more unstable due to the
enzymatic action of Asp49 PLA2, it would be less capable of
resisting a non-specific stress such as osmotic imbalance. Results
confirmed this assumption, showing that myotubes were signifi-
cantly more susceptible to the cytolysis induced by hypotonic
media if they were exposed to minute amounts of Asp49 PLA2
myotoxin. In contrast, myotubes exposed to equivalent amounts of
Lys49 myotoxin were equally susceptible to lysis in such hypotonic
media, as in the absence of toxin. Taken together, these
experiments indicate that the enhancing mechanism for the
toxicity of Lys49 myotoxins exerted by Asp49 PLA2 myotoxin
Figure 10. Cartoon representation of the hypothetical synergistic mechanism involved in the membrane-damaging activity of
Asp49 and Lys49 myotoxins. Toxins bind to the muscle cell membrane (A), although acceptor moieties for this event are unknown. Each toxin
type by its own has the ability to induce cytotoxicity in vitro or myonecrosis in vivo through membrane damage. Asp49 myotoxins destabilize the
membrane by the enzymatic hydrolysis of phospholipids (PL) and consequent production of lyso-PL and fatty acids (FA), whereas Lys49 myotoxins
exert a direct permeabilization mechanism via their C-terminal region (B). When acting in combination, FA produced by the Asp49 myotoxin generate
new anionic sites (red spheres) that facilitate the binding of Lys49 myotoxin through electrostatic interactions (C). The membrane becomes more
unstable due to PL hydrolysis per se, and to the accumulation of the reaction products (lysoPL and FA). As a result of these combined actions of Asp49
and Lys49 myotoxins, membrane damage is enhanced and the cell becomes irreversibly damaged (D). Note that the toxin cartoons are represented
as monomers for simplicity, although these toxins actually occur as homodimers. Cartoons are not drawn to scale, and the orientation of the toxins
interacting with the membrane is only for illustrative purposes.
doi:10.1371/journal.pone.0109846.g010
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involves at least the weakening of cell membrane integrity by the
latter. On the other hand, the possibility of the generation of new
anionic sites by the accumulation of products of catalysis in the
membrane remains to be tested, but clearly, both mechanisms
would rely on the enzymatic activity of the Asp49 PLA2 myotoxin
(Fig. 10).
The synergistic mechanism hereby characterized contributes to
rationalize the evolutionary advantage for the emergence of two
different subtypes of PLA2 myotoxins in the venom of many
viperids, which are known to use two contrasting molecular
mechanisms that lead to the same outcome: skeletal muscle
necrosis. The synergy between Asp49 and Lys49 myotoxins
represents at least one advantageous feature for the snakes, but
additional mechanisms of adaptive value for these toxins may also
exist [41], for example in their possible functional interactions with
other snake venom components [57,58]. On a more general
ground, our findings stress the need to study the action of snake
venoms from a holistic perspective, i.e. by analyzing not only the
action of purified toxins, but also the interaction of different
components in the context of the complexity of snakebite
envenoming.
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